Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

• Status: Completed
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Ampicillin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Sultamicillin; Tazobactam

Criteria

Inclusion Criteria

• Patients with diabetes mellitus

• Inpatient

• Have 1 or more infected ulcer(s) below the ankle

Exclusion Criteria

• Must not have gangrene or severely impaired arterial supply in your foot

• Must not have a bone infection in the area of your ulcer

• Must not have allergies to penicillins